There's no good evidence that supplementation with NMN, NR, etc. increases the risk of cancer in healthy people. There's some speculation that it might be risky for people with cancer to take those supplements, but the picture is far from clear. Some papers even suggest that they can be beneficial. (e.g., https://pmc.ncbi.nlm.nih.gov/articles/PMC10177531/ )

In terms of risk-benefit analysis, if this stuff actually cures Alzheimer's, then even a 10x increased risk of cancer (all types) is acceptable, as Alzheimer's is frequently a fate worse than death whereas cancer can be managed whilst keeping your personality and sanity intact. In reality, the increased risk of cancer from something like NMN is perhaps 1.005x. To all appearances, totally negligible.

The problem, for Pieper, is that NMN/NR/NADH are ubiquitous and cost pennies per dose. So, if they work (big if), this new research is unmonetizable. The team leads would win a Nobel Prize, but Big Pharma gigabucks are out of the question. Let's see what happens.

▲

nkmnz 17 hours ago | parent | next [-]

Could explain how a compound that's already on the market and has been patented for (some) medical use at least once in 2015 (expiring 2035) might make a good case for "Big Pharma gigabucks"? I thought one reason for a lack of research into "repurposablity" of existing small molecule drugs is the fact that new applications cannot be independently patented?

▲

cyberax 16 hours ago | parent [-]

You absolutely can patent existing drugs. There's a whole scummy pharma industry that takes existing drugs that are widely used off-label and patents that off-label use.

	▲	directevolve 15 hours ago \| parent \| next [-]
		I think it’s worth addressing this with more nuance. Companies can get a METHOD-OF-USE PATENT (MOU) on an old drug for a new INDICATION. This gives them the exclusive right to LABEL AND MARKET that drug for that indication for a period of time. I however, doctors can prescribe and pharmacists can substitute generics for the new indication, regardless of the MOU. For a company to profit off an MOU, they strategically need to create a new FORMULATION. This is a new dose or delivery mechanism (extended release, topical, etc). A new formulation can be protected with conventional patents that go beyond an MOU. With an MOU + patent on a new formulation, the company has a brand where they are the only ones allowed to make the new formulation and the only ones with a product approved to be marketed for the new indication. Getting FDA approval for the new brand is not the main hurdle for the company. To get insurers to pay the premium they want over the cost of existing treatment options, they have to show it’s safer or more effective than those existing options. Otherwise insurance will block it. In principle, this means that repurposing should only enable companies to profitably repurpose off patent off label applications if they can provide a real patient benefit. Whether this is the best or most efficient way to promote this kind of innovation, or whether it works as well in practice as it would seem in theory, is a separate question.
	▲	nkmnz 11 hours ago \| parent \| prev \| next [-]
		Could you name some examples so that I can read more about this?
	▲	rockskon 14 hours ago \| parent \| prev [-]
		You don't patent a use. You're thinking trademark.

▲

FooBarWidget 17 hours ago | parent | prev [-]

Furthermore, we don't even know whether NAD precursor supplementation works. They raise intracellular NAD+ levels, but unclear whether they raise intercellular NAD+, which is what really matters. There are also those that say NAD+ recycling matters more than we think, and precursors don't address that.

▲

JumpCrisscross 15 hours ago | parent [-]

> raise intracellular NAD+ levels, but unclear whether they raise intercellular NAD+, which is what really matters

Why?

	▲	FooBarWidget 13 hours ago \| parent [-]
		Urgh I made a mistake. I meant the other way around: intracellular matters more, but intercellular is easier to measure.